Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate (2022)

Peer-Reviewed Study · Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO · 2022

Wischik CM et al., 2022: Design paper for the LUCIDITY phase 3 trial that documents the low-dose oral hydromethylthionine mesylate regimen (16 mg/day) chosen for the trial. It is the published source for the 16 mg/day figure used in later tau trials.

Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase.

Wischik CM et al., 2022: Design paper for the LUCIDITY phase 3 trial that documents the low-dose oral hydromethylthionine mesylate regimen (16 mg/day) chosen for the trial. It is the published source for the 16 mg/day figure used in later tau trials. Study type: protocol/design paper for a phase 3 RCT (LUCIDITY). N=545 planned (446 expected to complete blinded phase). Countries: 76 sites in North America and Europe. Dose: hydromethylthionine mesylate (HMTM, LMTM) 16 mg/day or 8 mg/day orally vs placebo, 4:1:4; open-label phase 16 mg/day. Route: oral. Duration: 12-month double-blind + 12-month open-label. COI: 'C.M.W. is an employee and officer of TauRx Therapeutics Ltd. S.M, B.S and P.B are employees of TauRx Therapeutics Ltd… C.M.W and B.S. are inventors on patents relating to neurodegenerative diseases that are owned by WisTa Laborat…' (truncated in record). Maker: TauRx Therapeutics. Comparator: placebo. Note: the quoted word 'hydromethylthione' is the spelling in the source text. Study type: other.